We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 1-20 of 31 Articles
Patricio O’Donnell, MD, PhD; Michael D. Ehlers, MD, PhD

This Viewpoint discusses steps to accelerate innovation and advance new medicines for psychiatric disease.

The article by Peciña and colleagues1 in this issue of JAMA Psychiatry reports the results of a study evaluating with a neuroimaging paradigm the neurochemical mechanisms underlying the formation of placebo effects in patients with major depressive disorder (MDD). Their study involved performing a single-blinded 2-week crossover ...

Original Investigation 
Marta Peciña, MD, PhD; Amy S. B. Bohnert, PhD; Magdalena Sikora, BS; Erich T. Avery, BA; Scott A. Langenecker, PhD; Brian J. Mickey, MD, PhD; Jon-Kar Zubieta, MD, PhD
Includes: Supplemental Content

Importance  High placebo responses have been observed across a wide range of pathologies, severely impacting drug development.

Objective  To examine neurochemical mechanisms underlying the formation of placebo effects in patients with major depressive disorder (MDD).

Design, Setting, and Participants  In this study involving 2 placebo ...

Editorial: Placebo Response in Major Depressive Disorder; Maurizio Fava, MD
Original Investigation  FREE
David A. Brent, MD; Steven M. Brunwasser, PhD; Steven D. Hollon, PhD; V. Robin Weersing, PhD; Gregory N. Clarke, PhD; John F. Dickerson, PhD; William R. Beardslee, MD; Tracy R. G. Gladstone, PhD; Giovanna Porta, MS; Frances L. Lynch, PhD; Satish Iyengar, PhD; Judy Garber, PhD
Includes: Supplemental Content

Importance  Adolescents whose parents have a history of depression are at risk for developing depression and functional impairment. The long-term effects of prevention programs on adolescent depression and functioning are not known.

Objective  To determine whether a cognitive-behavioral prevention (CBP) program reduced the incidence of depressive ...

Original Investigation 
Erica S. Weitz, MA; Steven D. Hollon, PhD; Jos Twisk, PhD; Annemieke van Straten, PhD; Marcus J. H. Huibers, PhD; Daniel David, PhD; Robert J. DeRubeis, PhD; Sona Dimidjian, PhD; Boadie W. Dunlop, MD, MS; Ioana A. Cristea, PhD; Mahbobeh Faramarzi, PhD; Ulrich Hegerl, MD, PhD; Robin B. Jarrett, PhD; Farzan Kheirkhah, MD; Sidney H. Kennedy, MD; Roland Mergl, PhD; Jeanne Miranda, PhD; David C. Mohr, PhD; A. John Rush, MD; Zindel V. Segal, PhD; Juned Siddique, DrPH; Anne D. Simons, PhD; Jeffrey R. Vittengl, PhD; Pim Cuijpers, PhD
Includes: Supplemental Content

Importance  Current guidelines recommend treating severe depression with pharmacotherapy. Randomized clinical trials as well as traditional meta-analyses have considerable limitations in testing for moderators of treatment outcomes.

Objectives  To conduct a systematic literature search, collect primary data from trials, and analyze baseline depression severity as a ...

Comment & Response 
Melissa Raven, PhD

To the Editor The analysis by Walker et al1 of mortality in mental disorders inappropriately generalizes mortality estimates derived from clinical (primarily tertiary) samples, including high proportions of patients with psychotic disorders, to cases identified in population surveys. This markedly exaggerates the population mortality due to mental ...

Comment & Response 
Elizabeth Reisinger Walker, PhD, MPH, MAT; Robin E. McGee, MPH; Benjamin G. Druss, MD, MPH

In Reply Dr Raven highlights the importance of developing accurate population-based estimates of excess mortality among people with mental disorders. She raises several methodological issues that are relevant to developing estimates of disease burden in general and to understanding excess mortality in individuals with mental disorders in particular.

Ian R. H. Rockett, PhD, MPH; Eric D. Caine, MD

This Viewpoint discusses the false dichotomy of separating suicides from fatal self-injurious acts that are labeled “accidents” or “unintentional” deaths.

Sarah N. Garfinkel, PhD; Jessica A. Eccles, MBChB, MRCPsych; Hugo D. Critchley, MBChB, DPhil, FRCPsych, FRSB

Müller and colleagues1 present a study showing that an electroencephalographic signature of the brain’s representation of internal bodily responses (the amplitude of heartbeat evoked potential) is abnormally attenuated in patients with borderline personality disorder (BPD). This deficit predicts symptoms, including the degree of emotional instability, and correlates ...

Original Investigation 
Laura E. Müller, MSc; André Schulz, PhD; Martin Andermann, Dipl-Psych; Andrea Gäbel, PhD; Dorothee Maria Gescher, MD; Angelika Spohn, Dipl-Psych; Sabine C. Herpertz, MD; Katja Bertsch, PhD
Includes: Supplemental Content

Importance  The ability to perceive and regulate one’s own emotions has been tightly linked to the processing of afferent bodily signals (interoception). Thus, disturbed interoception might contribute to the core feature of emotional dysregulation in borderline personality disorder (BPD), as increased levels of depersonalization, body image disturbances, ...

Editorial: The Heart, the Brain, and the Regulation of Emotion; Sarah N. Garfinkel, PhD; Jessica A. Eccles, MBChB, MRCPsych; Hugo D. Critchley, MBChB, DPhil, FRCPsych, FRSB

Low resting heart rate (RHR) has for some time been suspected to be a risk factor for crime and violence. One prior meta-analysis of 40 studies with a combined sample of 5868 individuals documented an association between low RHR and high antisocial and aggressive behavior in child and ...

Amit Shah, MD, MSCR; Viola Vaccarino, MD, PhD

Posttraumatic stress disorder (PTSD) is a relatively common condition, with a 7% to 9% lifetime prevalence in US civilians and a 15% to 19% lifetime prevalence in combat veterans.1 Neurobiological dysregulation of autonomic nervous system pathways involved in the stress response has long been considered a hallmark ...

Original Investigation  FREE
Arpi Minassian, PhD; Adam X. Maihofer, MS; Dewleen G. Baker, MD; Caroline M. Nievergelt, PhD; Mark A. Geyer, PhD; Victoria B. Risbrough, PhD; for the Marine Resiliency Study Team
Includes: Supplemental Content

Importance  Disrupted autonomic nervous system functioning as measured by heart rate variability (HRV) has been associated with posttraumatic stress disorder (PTSD). It is not clear, however, whether reduced HRV before trauma exposure contributes to the risk for development of PTSD.

Objective  To examine whether HRV before ...

Editorial: Heart Rate Variability in Prediction of PTSD; Amit Shah, MD, MSCR; Viola Vaccarino, MD, PhD
Original Investigation 
Antti Latvala, PhD; Ralf Kuja-Halkola, PhD; Catarina Almqvist, PhD; Henrik Larsson, PhD; Paul Lichtenstein, PhD
Includes: Supplemental Content

Importance  Low resting heart rate is a well-replicated physiological correlate of aggressive and antisocial behavior in children and adolescents, but whether low resting heart rate increases the risk of violence and other antisocial and risk-taking behaviors in adulthood has not been studied in representative samples.

Objective  ...

Original Investigation 
Kimberly A. Yonkers, MD; Susan G. Kornstein, MD; Ralitza Gueorguieva, PhD; Brian Merry, MS; Kari Van Steenburgh, BA; Margaret Altemus, MD
Includes: Supplemental Content

Importance  Serotonin reuptake inhibitors (SRIs) are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily or for half of the menstrual cycle during the luteal phase. Preliminary studies suggest that SRI treatment can be shortened to the interval from symptom onset through the beginning of menses....

Research Letter 
Gregory E. Simon, MD, MPH; Karen J. Coleman, PhD; Beth E. Waitzfelder, PhD; Arne Beck, PhD; Rebecca C. Rossom, MD, MS; Christine Stewart, PhD; Robert B. Penfold, PhD

This cohort study across 5 health systems examines how stratifying by race/ethnicity would affect a specific mental health care quality measure: the proportion of outpatients starting antidepressant treatment who receive adequate or potentially effective acute-phase treatment.

Comment & Response 
Michael Berk, MD, PhD

To the Editor In JAMA Psychiatry, Pine and Leibenluft1 highlighted the importance of biomarkers in elucidating mechanisms. However, there is an issue regarding the nomenclature of biomarkers that clouds the field in that the term biomarker is typically used as an interchangeable umbrella term for a ...

Original Investigation 
Angela Heck, PhD; Matthias Fastenrath, PhD; David Coynel, PhD; Bianca Auschra, MS; Horst Bickel, PhD; Virginie Freytag, MS; Leo Gschwind, MS; Francina Hartmann, MS; Frank Jessen, MD; Hanna Kaduszkiewicz, MD; Wolfgang Maier, MD; Annette Milnik, MD; Michael Pentzek, PhD; Steffi G. Riedel-Heller, MD; Klara Spalek, PhD; Christian Vogler, PhD; Michael Wagner, PhD; Siegfried Weyerer, PhD; Steffen Wolfsgruber, MS; Dominique J.-F. de Quervain, MD; Andreas Papassotiropoulos, MD
Includes: Supplemental Content

Importance  Human episodic memory performance is linked to the function of specific brain regions, including the hippocampus; declines as a result of increasing age; and is markedly disturbed in Alzheimer disease (AD), an age-associated neurodegenerative disorder that primarily affects the hippocampus. Exploring the molecular underpinnings of human ...

Original Investigation 
Chris H. Miller, BS; J. Paul Hamilton, PhD; Matthew D. Sacchet, ScB; Ian H. Gotlib, PhD
Includes: Supplemental Content

Importance  Despite its high prevalence and morbidity, the underlying neural basis of major depressive disorder (MDD) in youth is not well understood.

Objectives  To identify in youth diagnosed as having MDD the most reliable neural abnormalities reported in existing functional neuroimaging studies and characterize their relations ...

David Goldman, MD

Cannabis is widely used, psychoactive, and addictive. Given the choice, people in several US states and the District of Columbia have voted to legalize it. In the nation’s capital, it is now legal to possess as many as 3 Cannabis sativa plants. Meanwhile, it remains illegal to have ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts